Published in Biol Blood Marrow Transplant on January 01, 2012
Targeted Therapy of Bronchiolitis Obliterans Syndrome (FAM for BOS) | NCT01307462
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease | NCT01155817
NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch Dermatol Res (2013) 0.79
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Clinical transplantation of a tissue-engineered airway. Lancet (2008) 10.04
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 5.92
Tissue-engineered lungs for in vivo implantation. Science (2010) 5.90
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med (2010) 5.59
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med (2009) 2.63
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A (2010) 2.44
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 2.25
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest (2010) 1.90
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA (2009) 1.88
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant (2011) 1.85
New insights into form and function of fibronectin splice variants. J Pathol (2008) 1.80
Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology (2011) 1.73
Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest (2002) 1.69
Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant (2011) 1.66
Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant (2003) 1.65
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood (2007) 1.60
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.57
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood (2009) 1.46
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 1.44
Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol (2005) 1.40
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica (2006) 1.32
Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia (2006) 1.24
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res (2005) 1.10
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica (2011) 1.10
Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol (2007) 1.05
Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children. Biol Blood Marrow Transplant (2009) 1.00
Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol (2002) 0.97
Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas (2009) 0.96
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist (2002) 0.93
Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2006) 0.93
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis (2010) 0.91
Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant (2010) 0.88
The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts. Arthritis Res Ther (2010) 0.83
Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis. Int J Immunopathol Pharmacol (2010) 0.79
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A (2004) 3.82
Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem (2003) 3.51
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal (2006) 2.22
Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med (2009) 2.15
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood (2004) 1.86
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood (2011) 1.83
The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol (2013) 1.73
FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med (2014) 1.72
Allowing adolescents and young adults to plan their end-of-life care. Pediatrics (2012) 1.59
Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol (2012) 1.57
Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest (2014) 1.54
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J (2009) 1.41
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol (2004) 1.34
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis (2007) 1.34
Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol (2005) 1.33
Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. J Clin Invest (2013) 1.31
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest (2010) 1.27
Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol (2010) 1.23
Pulmonary sarcoidosis. Semin Respir Crit Care Med (2007) 1.19
PGE(2) inhibition of TGF-beta1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol (2007) 1.19
EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J (2010) 1.11
Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol (2011) 1.08
Leptin modulates neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun (2003) 1.06
Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect Immun (2010) 1.05
Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med (2015) 1.04
Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Exp Cell Res (2010) 1.03
Usual interstitial pneumonia. Semin Respir Crit Care Med (2006) 1.02
Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol (2011) 0.99
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol (2012) 0.99
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol (2007) 0.99
Activation of phosphatase and tensin homolog on chromosome 10 mediates the inhibition of FcgammaR phagocytosis by prostaglandin E2 in alveolar macrophages. J Immunol (2007) 0.98
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. Infect Immun (2011) 0.96
Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. Arch Dermatol (2011) 0.96
Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infect Immun (2012) 0.95
Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med (2015) 0.94
Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.94
X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis. Am J Respir Cell Mol Biol (2013) 0.92
PTEN directly activates the actin depolymerization factor cofilin-1 during PGE2-mediated inhibition of phagocytosis of fungi. Sci Signal (2012) 0.92
The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol (2009) 0.91
Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am (2010) 0.90
Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res (2014) 0.90
Phosphatase and tensin homologue on chromosome 10 (PTEN) directs prostaglandin E2-mediated fibroblast responses via regulation of E prostanoid 2 receptor expression. J Biol Chem (2009) 0.89
Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol (2012) 0.89
Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med (2008) 0.88
Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2009) 0.88
Tissue inhibitor of matrix-metalloprotease-1 predicts risk of hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis (2011) 0.87
Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy. Pediatr Infect Dis J (2008) 0.87
PTEN limits alveolar macrophage function against Pseudomonas aeruginosa after bone marrow transplantation. Am J Respir Cell Mol Biol (2011) 0.84
Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol (2006) 0.84
Schistosoma japonicum soluble egg antigens attenuate invasion in a first trimester human placental trophoblast model. PLoS Negl Trop Dis (2013) 0.84
Maternal infection with Schistosoma japonicum induces a profibrotic response in neonates. Infect Immun (2013) 0.84
Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol (2009) 0.83
Pneumocystis pneumonia increases the susceptibility of mice to sublethal hyperoxia. Infect Immun (2003) 0.80
Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study. Support Care Cancer (2014) 0.80
Systemic hypersensitivity reaction mimicking anaphylaxis after first filgrastim administration in a healthy donor. Transfusion (2013) 0.80
An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. Am J Respir Crit Care Med (2016) 0.79
Understanding chronic GVHD from different angles. Biol Blood Marrow Transplant (2012) 0.78
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol (2017) 0.77
Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol (2014) 0.77
Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al. Arthritis Rheumatol (2014) 0.77
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges. Am J Hematol (2012) 0.77
Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol (2014) 0.77
Enhancing immune reconstitution: from bench to bedside. Biol Blood Marrow Transplant (2012) 0.76
Innate pathways shape sarcoidosis signaling: from bugs to drugs. Am J Respir Crit Care Med (2011) 0.75
Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma. Pediatr Blood Cancer (2009) 0.75
Infliximab in sarcoidosis: more answers or more questions? Am J Respir Crit Care Med (2006) 0.75
What do parents want to know when considering autopsy for their child with cancer? J Pediatr Hematol Oncol (2014) 0.75
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci Rep (2017) 0.75